Gaudium IVF IPO is opening for public subscription on February 20, 2026 and will close on February 24, 2026. The issue is being launched by Gaudium IVF & Women’s Health Ltd. as a book build issue with a price band of ₹75 to ₹79 per equity share.
The company aims to raise approximately ₹165 crores through a mix of fresh issue and offer for sale. The basis of allotment is expected on February 25, 2026, while the shares are proposed to be listed on BSE and NSE on February 27, 2026. The company operates a growing network of IVF and women’s healthcare centres across India and overseas markets.
Contents
Gaudium IVF IPO Details
| Particular | Details |
|---|---|
| IPO Open Date | February 20, 2026 |
| IPO Close Date | February 24, 2026 |
| Face Value | ₹5 per equity share |
| IPO Price Band | ₹75 to ₹79 per share |
| Issue Size | Approx ₹165 crores |
| Fresh Issue | Approx ₹90 crores |
| Offer for Sale | Approx 94,93,700 equity shares |
| Issue Type | Book build issue |
| IPO Listing | BSE, NSE |
| DRHP Draft Prospectus | View PDF |
| RHP Draft Prospectus | View PDF |
Gaudium IVF IPO
Open: 20-24 Feb
Issue Size: ₹165 Cr.
Objective: To fund new IVF centres and expand fertility services network.
Exchange: BSE NSE
Gaudium IVF IPO review
Gaudium IVF IPO is rated as neutral. The company operates in the specialised fertility and women’s health segment, with improving revenues and profitability over the last two years. The business caters to both domestic and international clients with a range of IVF and fertility treatments.
Strong growth in revenue and PAT suggests expanding operations and customer demand. However, investors should consider competitive pressures in healthcare services, regulatory dynamics and operating costs. Those with a long-term view and familiarity with healthcare services might consider this IPO as a strategic addition, while keeping moderate risk expectations.
Gaudium IVF IPO price band and quota
| Category | Shares (%) |
|---|---|
| Anchor Investor | 30% |
| QIB (Excluding Anchor) | 20% |
| NII | 15% |
| Retail | 35% |
Gaudium IVF IPO market lot
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 189 | ₹14,931 |
| Retail Maximum | 13 | 2,457 | ₹1,94,103 |
| S-HNI Minimum | 14 | 2,646 | ₹2,09,034 |
| S-HNI Maximum | 66 | 12,474 | ₹9,85,446 |
| B-HNI Minimum | 67 | 12,663 | ₹10,00,377 |
Gaudium IVF IPO anchor investors
| Particular | Details |
|---|---|
| Anchor Bidding Date | February 19, 2026 |
| Anchor Investors List | View PDF |
| Shares Offered | 62,65,860 shares |
| Anchor Size | ₹49.50 crores |
| Lock-in (50% – 30 days) | March 27, 2026 |
| Lock-in (50% – 90 days) | May 26, 2026 |
Gaudium IVF IPO dates
| Event | Date |
|---|---|
| IPO Open Date | February 20, 2026 |
| IPO Close Date | February 24, 2026 |
| Basis of Allotment | February 25, 2026 |
| Refunds | February 26, 2026 |
| Credit to Demat Account | February 26, 2026 |
| IPO Listing Date | February 27, 2026 |
| IPO Bidding Cut-off Time | February 24, 2026 – 5 PM |
Promoters and holding pattern
The promoters of the company are Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna.
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 6,13,94,384 | 99.99% |
| Promoter Holding Post Issue | 7,27,86,884 | 71.30% |
Objects of the issue
The company plans to use ₹50 crores for funding capital expenditure towards establishing new IVF centres. Another ₹20 crores will be used for full or part repayment/pre-payment of certain outstanding loans. The remaining funds will be deployed for general corporate purposes to support strategic expansion.
About Gaudium IVF
Founded in March 2015, Gaudium IVF & Women’s Health Ltd. is a leading IVF and fertility services provider in India. The company operates in over 30 locations with seven hubs and twenty-eight spokes. It treats patients from India and international markets including Canada, the United Kingdom, the United States, Kenya, South Africa and Oman.
The firm offers a wide range of fertility services such as IVF, intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI) and ovulation induction. It also provides solutions for PCOD/PCOS, endometriosis and advanced care for male infertility, including sperm retrieval procedures.
Business Analysis and Financial Health
Gaudium IVF operates in the specialist healthcare services segment with a focus on fertility treatments and women’s health. The firm has demonstrated strong revenue and profit growth, with revenue rising from ₹48.15 crores in FY2024 to ₹70.96 crores in FY2025, and PAT increasing from ₹10.32 crores to ₹19.13 crores over the same period.
It also delivered healthy margins and return ratios, supported by an expanding asset base and efficient capital management. High ROE and ROCE indicate strong operational performance and profitability.
The business is positioned for long-term growth, underpinned by increasing demand for IVF and related services, continuity of high clinical standards, and wider geographic presence across domestic and international markets.
Gaudium IVF IPO company financials
| Period Ended | Revenue | Expense | PAT | Assets (₹ in crores) |
|---|---|---|---|---|
| 2023 | 44.26 | 25.95 | 13.53 | 36.63 |
| 2024 | 48.15 | 31.52 | 10.32 | 51.01 |
| 2025 | 70.96 | 45.54 | 19.13 | 88.51 |
| Sep 2025 | 49.75 | 32.97 | 12.51 | 106.62 |
Gaudium IVF IPO valuation – FY2025
| KPI | Values |
|---|---|
| ROE | 41.31% |
| ROCE | 39.70% |
| EBITDA Margin | 40.48% |
| PAT Margin | 26.96% |
| Debt to Equity Ratio | 0.41 |
| Earning Per Share (EPS) | ₹3.12 (Basic) |
| Price/Earning Ratio | N/A |
| Return on Net Worth | 41.71% |
| Net Asset Value | ₹7.54 |
Peer group comparison
There are no directly listed industry peers for Gaudium IVF.
IPO lead managers
| Lead Manager | Details |
|---|---|
| Lead Manager | Sarthi Capital Advisors Pvt. Ltd. |
Company address
| Particular | Details |
|---|---|
| Company Name | Gaudium IVF & Women’s Health Ltd. |
| Registered Office | B1/51, Janak Puri, New Delhi, Delhi – 110058 |
| Phone | 011-4885 8585 |
| compliance@gaudiumivfcentre.com | |
| Website | https://www.gaudiumivfcentre.com/ |
IPO registrar
| Registrar | Details |
|---|---|
| Name | Bigshare Services Pvt. Ltd. |
| Phone | +91-22-6263 8200 |
| ipo@bigshareonline.com | |
| Website | https://ipo.bigshareonline.com/IPO_Status.html |
Gaudium IVF IPO FAQs
What is Gaudium IVF IPO?
Gaudium IVF IPO is a mainboard IPO where the company plans to raise ₹165 crores through a book build issue at a price band of ₹75 to ₹79 per share. The IPO is proposed to be listed on BSE and NSE.
When will Gaudium IVF IPO open for subscription?
The IPO opens on February 20, 2026 and closes on February 24, 2026.
What is the investors’ portion in Gaudium IVF IPO?
The IPO offers 50% quota to QIBs (including anchor), 15% to NIIs, and 35% to retail investors.
How to apply for Gaudium IVF IPO?
Investors can apply through ASBA using bank accounts, UPI via brokers, or by submitting offline forms through brokers.
What is Gaudium IVF IPO issue size?
The total issue size is approximately ₹165 crores.
What is the Gaudium IVF IPO price band?
The price band is ₹75 to ₹79 per share.
What is the lot size of Gaudium IVF IPO?
The minimum bid size is 189 shares, requiring an application amount of ₹14,931.
What is the allotment date of Gaudium IVF IPO?
The basis of allotment is expected on February 25, 2026.
What is the listing date of Gaudium IVF IPO?
The IPO is scheduled to be listed on February 27, 2026 on BSE and NSE.
Expert Comment
Gaudium IVF IPO presents an opportunity to participate in a niche healthcare services company with a strong growth trajectory in fertility and women’s health treatments. With improving revenues, robust profitability and expanding geographic presence, the company is well positioned in a growing market.
However, investors should consider industry dynamics, regulatory shifts and execution strategies when evaluating the issue. Long-term investors with moderate risk appetite may find the IPO attractive, provided they assess valuation and future growth prospects carefully.
